Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Other · 2024

Zelsuvmi (berdazimer)

The FDA approved Zelsuvmi (berdazimer) on January 5, 2024 to treat molluscum contagiosum.
Brand name
Zelsuvmi
Generic name
berdazimer
FDA approval date
January 5, 2024
Approved use (FDA wording)
To treat molluscum contagiosum
Company
Lnhc
Application
NDA217424
Dosage form / route
GEL · TOPICAL
Boxed warning on label
Not listed
Category on this site
Other

Indications and usage, from the FDA label

ZELSUVMI™ is indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older. ZELSUVMI™ is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older. ( 1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.